as of 09-16-2026 10:17am EST
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 1.2M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 43.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | 45.13 |
| 52 Week Low/High: | $0.54 - $2.89 | Next Earning Date: | 05-13-2026 |
| Revenue: | $1,070,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.63 | Index: | N/A |
| Free Cash Flow: | -2691654.0 | FCF Growth: | N/A |
See how BBLG stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BBLG Bone Biologics Corp - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.